APRE Logo

Aprea Therapeutics, Inc. (APRE) 

NASDAQ$2.39
Market Cap
$12.99M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
260 of 922
Rank in Industry
149 of 526

APRE Insider Trading Activity

APRE Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$165,941990
Sells
$29,583110

Related Transactions

Duey Marcdirector2$132,1901$29,583$102,607
Seizinger Bernd R.director1$26,8000$0$26,800
Gilad OrenPresident/CEO4$5,6540$0$5,654
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr2$1,2980$0$1,298

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Insider Activity of Aprea Therapeutics, Inc.

Over the last 12 months, insiders at Aprea Therapeutics, Inc. have bought $165,941 and sold $29,583 worth of Aprea Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aprea Therapeutics, Inc. have bought $162,430 and sold $31.43M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Duey Marc (director) — $132,190. Seizinger Bernd R. (director) — $26,800. Gilad Oren (President/CEO) — $5,654.

The last purchase of 500 shares for transaction amount of $1,958 was made by Gilad Oren (President/CEO) on 2024‑10‑23.

List of Insider Buy and Sell Transactions, Aprea Therapeutics, Inc.

2024-10-23PurchaseGilad OrenPresident/CEO
500
0.0086%
$3.92$1,958-13.59%
2024-10-18SaleDuey Marcdirector
6,462
0.1238%
$4.58$29,583-22.39%
2024-10-16PurchaseDuey Marcdirector
30,000
0.8303%
$4.39$131,700-2.14%
2024-10-15PurchaseGilad OrenPresident/CEO
250
0.0046%
$2.90$725+12.46%
2024-10-14PurchaseGilad OrenPresident/CEO
1,000
0.0163%
$2.59$2,590+33.79%
2024-10-14PurchaseDuey Marcdirector
190
0.0031%
$2.58$490+33.79%
2024-10-11PurchaseSeizinger Bernd R.director
10,000
0.169%
$2.68$26,800+31.54%
2024-10-11PurchaseHamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
50
0.0008%
$2.46$123+31.54%
2024-10-10PurchaseGilad OrenPresident/CEO
150
0.0024%
$2.54$381+34.45%
2024-10-10PurchaseHamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
450
0.0074%
$2.61$1,175+34.45%
2024-03-13PurchaseGilad OrenPresident, CEO
2,000
0.0683%
$7.29$14,580-31.53%
2024-03-13PurchaseSeizinger Bernd R.director
6,860
0.2342%
$7.29$50,009-31.53%
2024-03-13PurchaseHamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
1,010
0.0345%
$7.29$7,363-31.53%
2024-03-13PurchaseHENNEMAN JOHN B IIIdirector
6,860
0.2342%
$7.29$50,009-31.53%
2023-06-07PurchaseSeizinger Bernd R.director
6,029
0.1917%
$3.68$22,192+18.87%
2023-06-06PurchaseSeizinger Bernd R.director
4,068
0.1208%
$3.63$14,764+11.20%
2020-12-28SaleRedmile Group, LLC10 percent owner
500,000
2.4014%
$5.58$2.79M-11.73%
2020-10-05Sale5AM Ventures IV, L.P.Former 10% holder
175,000
0.7844%
$25.30$4.43M-80.91%
2020-07-07SaleKDev Investments AB10 percent owner
241,703
1.1593%
$34.55$8.35M-79.65%
2020-06-16SaleROCKLAGE SCOTT MFormer 10% holder
120,164
0.5556%
$33.30$4M-38.45%
Total: 38
*Gray background shows transactions not older than one year

Insider Historical Profitability

30.38%
Gilad OrenPresident/CEO
333395
6.1343%
$796,814.0550<0.0001%
Duey Marcdirector
233651
4.2991%
$558,425.8921
Seizinger Bernd R.director
44730
0.823%
$106,904.7040<0.0001%
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
19368
0.3564%
$46,289.5230<0.0001%
Christenson Johandirector
2366104
43.5354%
$5.65M10+53.58%
HealthCap VII, L.P.10 percent owner
2366104
43.5354%
$5.65M10+53.58%
KDev Investments AB10 percent owner
1992586
36.6628%
$4.76M02
Redmile Group, LLC10 percent owner
1768718
32.5437%
$4.23M11+53.58%
Versant Vantage I, L.P.10 percent owner
333333
6.1332%
$796,665.8710+53.58%
Versant V Luxco S.a r.l.10 percent owner
333333
6.1332%
$796,665.8710+53.58%
5AM Ventures IV, L.P.Former 10% holder
138497
2.5483%
$331,007.8314+53.58%
ROCKLAGE SCOTT MFormer 10% holder
75965
1.3977%
$181,556.3503
HENNEMAN JOHN B IIIdirector
8139
0.1498%
$19,452.2120+11.02%
Magni Guidodirector
6500
0.1196%
$15,535.0010+53.58%
SCHADE CHRISTIAN SPresident & CEO
5000
0.092%
$11,950.0010+53.58%
Coiante Scott MSVP, Chief Financial Officer
2500
0.046%
$5,975.0010+53.58%
Korbel Gregory AlanVP of Business Dev't
500
0.0092%
$1,195.0010+53.58%
Attar Eyal C.SVP, Chief Medical Officer
200
0.0037%
$478.0010+53.58%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$8,253,997
122
-53.40%
$12.32M
$992,222,850
90
-12.52%
$12.4M
$1,724,269
63
-16.36%
$12.18M
$8,900,811
57
-24.79%
$13.53M
$296,936
37
-18.12%
$13.91M
$383,884
32
-25.10%
$13.89M
$95,303,339
30
-13.78%
$12.59M
$86,569,038
18
-12.64%
$11.53M
$114,371,781
18
-1.31%
$12.97M
$112,810,270
18
-1.20%
$13.39M
Aprea Therapeutics, Inc.
(APRE)
$29,469,413
18
30.38%
$12.99M
$122,973
15
-26.96%
$12.36M
$490,284
15
-19.03%
$10.39M
$941,975
12
-10.74%
$12.19M
$389,864
11
12.52%
$14.5M
$36,538,405
10
-21.99%
$15.07M
$38,247,728
10
-10.97%
$13.9M
$11,777,042
10
-11.94%
$13.06M
$2,891,537
8
-39.31%
$13.82M

APRE Institutional Investors: Active Positions

Increased Positions10+47.62%87,793+4.39%
Decreased Positions5-23.81%11,500-0.57%
New Positions5New64,455New
Sold Out Positions<1Sold Out899Sold Out
Total Postitions26+23.81%2M+3.81%

APRE Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Aigh Capital Management Llc$1,294.0010.79%539,30000%2024-12-31
Sio Capital Management, Llc$664.005.53%276,60300%2024-12-31
Sphera Funds Management Ltd.$648.005.4%270,00000%2024-12-31
Nantahala Capital Management, Llc$494.004.12%205,76000%2024-12-31
Vanguard Group Inc$417.003.48%173,84200%2024-12-31
Stonepine Capital Management, Llc$358.002.98%149,221+12,047+8.78%2024-12-31
Dafna Capital Management Llc$329.002.74%137,17400%2024-12-31
Exome Asset Management Llc$307.002.56%127,960-9,214-6.72%2024-12-31
Geode Capital Management, Llc$102.000.85%42,663+2,596+6.48%2024-12-31
Morgan Stanley$88.000.74%36,808+2,600+7.6%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.